Our in vitro final results suggest that EAM-2201 needs to be examined with regard to probable in vivo pharmacokinetic drug–drug interactions because of time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 pursuits and competitive inhibition of UGT1A3 activity. This is a preview of membership content, log in by using an https://kirkx727gvk0.slypage.com/profile